Cargando…

Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC

INTRODUCTION: Previous studies have described improvements on lipid parameters when switching from other antiretroviral drugs to tenofovir (TDF) and impairments in lipid profile when discontinuing TDF. [1–3] It is unknown, however, if TDF has an intrinsic lipid-lowering effect or such findings are d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramón Santos, José, Saumoy, María, Curran, Adrian, Bravo, Isabel, Navarro, Jordi, Estany, Carla, Podzamczer, Daniel, Ribera, Esteban, Negredo, Eugenia, Clotet, Bonaventura, Paredes, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224859/ https://www.ncbi.nlm.nih.gov/pubmed/25394057 http://dx.doi.org/10.7448/IAS.17.4.19550

Ejemplares similares

Premier cas de pustulose généralisée induite par le vaccin anti-COVID-19
por: Abdelli, Wissal, et al.
Publicado: (2021)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study
por: Podzamczer, Daniel, et al.
Publicado: (2014)

Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial
por: Curran, Adrian, et al.
Publicado: (2020)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
por: Peng, Siyang, et al.
Publicado: (2014)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis
por: Arribas, Jose, et al.
Publicado: (2014)

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera(®)). Efficacy and safety analysis. GeSida Study 8114
por: Pérez-Hernández, Isabel A, et al.
Publicado: (2014)

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Wiriyatanakorn, Sirichai, et al.
Publicado: (2019)

Cloning and Characterizing Cytokine Genes from Seba's Short-tailed Bat (Carollia perspicillata)
por: Schountz, T., et al.
Publicado: (2008)

AGAMAGLOBULINEMIA LIGADA AO X E COVID‐19: RELATO DE CASO DE MELHORA APÓS USO DO PLASMA CONVALESCENTE
por: Cabral, Máderson Alvares de Souza, et al.
Publicado: (2021)

Impact des inhibiteurs de checkpoints immunitaires au cours de la COVID-19 chez les patients atteints de mélanome
por: Yatim, N., et al.
Publicado: (2021)

IMPLEMENTAÇÃO DE PROGRAMA INFORMATIZADO DE GERENCIAMENTO DE ANTIMICROBIANOS: DESAFIOS DURANTE A PANDEMIA DO COVID-19
por: Sudbrack, Leticia Olivier, et al.
Publicado: (2022)

AVALIAÇÃO DAS AÇÕES DO SERVIÇO DE CONTROLE DE INFECÇÃO HOSPITALAR NO CONTROLE DE MICRORGANISMOS MULTIRRESISTENTES NAS UTI DE UM HOSPITAL TERCIÁRIO DURANTE A PANDEMIA DE COVID-19
por: Rodrigues, Kelvi Diniz, et al.
Publicado: (2022)

Vaccination SARS-CoV-2 chez les patients atteints de sclérodermie systémique et traités par autogreffe de cellules souches hématopoïétiques, au nom du Groupe MATHEC-SFGM-TC
por: Biard, L., et al.
Publicado: (2023)

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
por: Di Yacovo, Silvana, et al.
Publicado: (2014)

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
por: Martínez, E, et al.
Publicado: (2010)

Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner
por: Echeverría, Patricia, et al.
Publicado: (2014)

Association between lipid genetic and immunological status in chronically HIV-infected patients
por: Echeverría, Patricia, et al.
Publicado: (2014)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
por: Hagins, D, et al.
Publicado: (2018)

Naïve patients receiving TDF/FTC-EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pill
por: Perez-Valero, I, et al.
Publicado: (2010)

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
por: Munderi, Paula, et al.
Publicado: (2019)

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily
por: Tiraboschi, Juan, et al.
Publicado: (2014)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
por: Lazzarin, A, et al.
Publicado: (2010)

Long-term fat redistribution in ARV-naïve HIV+ patients initiating a non-thymidine containing regimen in clinical practice
por: Ferrer, Elena, et al.
Publicado: (2014)

Efficacy and safety of TDF+FTC+EFV in naïve patients initiating HAART; an observational study comparing Atripla Vs Truvada/Sustiva exposure
por: Sanchez, Carlos Alberto, et al.
Publicado: (2010)

High Prevalence of Sarcopenia in HIV-Infected Individuals
por: Echeverría, Patricia, et al.
Publicado: (2018)

Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity
por: Bonjoch, Anna, et al.
Publicado: (2016)

Adherence to daily, oral TDF/FTC PrEP during periconception among HIV-exposed South African women
por: Hurwitz, Kathleen E., et al.
Publicado: (2023)

Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death
por: Casadellà Fontdevila, Maria, et al.
Publicado: (2014)

1298. Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis: A Case Report
por: Cohen, Stephanie E, et al.
Publicado: (2018)

Hidden costs of HIV treatment in Spain: inefficiency of the antiretroviral drug packaging
por: Llibre-Codina, Josep M, et al.
Publicado: (2014)

Efficacy and safety of TDF/FTC-containing, first-line HAART in clinical practice: 3-year data from the German outpatient cohort
por: van Lunzen, J, et al.
Publicado: (2010)

Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
por: Billaud, E, et al.
Publicado: (2010)

1024. Impact of Treatment Adherence on Efficacy of DTG/3TC and DTG + TDF/FTC: Pooled Analysis of the GEMINI 1 and 2 Clinical Trials
por: Ait-Khaled, Mounir, et al.
Publicado: (2020)

EFICÁCIA E TOXICIDADE DE TENOFOVIR (TDF) E ENTRICITABINA (FTC) PARA INFECÇÕES LEVE A MODERADA PELO SARS-COV-2
por: de Arruda, Erico Antonio Gomes, et al.
Publicado: (2022)

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
por: Santos, José R., et al.
Publicado: (2012)

HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
por: Baran, RW, et al.
Publicado: (2010)

How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP
por: Pilkington, Victoria, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0b3k0t73iteddghp8ltqqoq080